Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets. Sartorius Stedim Biotech's Goodwill for the quarter that ended in Jun. 2026 was €2,894 Mil. Sartorius Stedim Biotech's Total Assets for the quarter that ended in Jun. 2026 was €7,918 Mil.
Therefore, Sartorius Stedim Biotech's Goodwill to Asset Ratio for the quarter that ended in Jun. 2026 was 0.37.
If the goodwill-to-asset ratio increases, it can mean that the company is recording a proportionately higher amount of goodwill, assuming total assets are remaining constant. It is generally good to see a company increasing its assets regularly; however, if these increases are coming from intangible assets, such as goodwill, the increases may not be as good.
Increases in the goodwill-to-asset ratio might suggest that a company has been aggressively acquiring other firms or has seen its tangible assets decrease in value. When a large portion of total assets are attributable to intangible assets (such as goodwill), the company may be at risk of having that portion of its asset base wiped out quickly if it must record any goodwill impairments. Decreases in the goodwill-to-assets ratio suggest that the company has either written down some goodwill or increased its tangible assets.
Asset needs vary from industry to industry. This is why comparing goodwill-to-assets ratios is generally most meaningful among companies within the same industry. By comparing a company's goodwill to assets ratio to those of other companies within the same industry, investors can get a feel for how a company is managing its goodwill.
Sartorius Stedim Biotech Goodwill-to-Asset Related Terms
Sartorius Stedim Biotech Goodwill-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:DIMP vs ISRG, BDX, MDLN: Goodwill-to-Asset Comparison
For the Medical Instruments & Supplies subindustry, Sartorius Stedim Biotech's Goodwill-to-Asset, along with its competitors' market caps and Goodwill-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sartorius Stedim Biotech Goodwill-to-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sartorius Stedim Biotech's Goodwill-to-Asset distribution charts can be found below:
* The bar in red indicates where Sartorius Stedim Biotech's Goodwill-to-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sartorius Stedim Biotech (CHIX:DIMP) has a Goodwill-to-Asset of 0.37 as of Jun. 2026. Goodwill-to-Asset Ratio is the total goodwill from acquisitions divided by total assets. View historical data on Sartorius Stedim Biotech and its competitors.
Is Sartorius Stedim Biotech's Goodwill-to-Asset too high?
Sartorius Stedim Biotech's current Goodwill-to-Asset is 0.37. Overall, Sartorius Stedim Biotech has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sartorius Stedim Biotech's Goodwill-to-Asset compare to ISRG and BDX?
Sartorius Stedim Biotech's Goodwill-to-Asset of 0.37 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Goodwill-to-Asset for a Medical Devices & Instruments company?
A good Goodwill-to-Asset depends on the Medical Devices & Instruments industry context. However, Goodwill-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Goodwill-to-Asset mean?
A high Goodwill-to-Asset can signal that a stock is expensive relative to its fundamentals. Goodwill-to-Asset Ratio is the total goodwill from acquisitions divided by total assets. View historical data on Sartorius Stedim Biotech and its competitors. Sartorius Stedim Biotech's current Goodwill-to-Asset is 0.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sartorius Stedim Biotech stock overvalued right now?
Based on GuruFocus' analysis, Sartorius Stedim Biotech (CHIX:DIMP) is currently considered Modestly Undervalued. The stock's GF Value™ is €201.74, compared to a current price of €181.10 — trading 10.2% below its estimated fair value. The current Goodwill-to-Asset is 0.37. Sartorius Stedim Biotech's overall GF Score™ is 84/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Goodwill-to-Asset calculated?
Goodwill-to-Asset is calculated from a company's financial statements. For Sartorius Stedim Biotech (CHIX:DIMP), the current Goodwill-to-Asset is 0.37 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sartorius Stedim Biotech (CHIX:DIMP) Overvalued in 2026?
Based on GuruFocus' analysis, Sartorius Stedim Biotech stock appears to be undervalued.
The current stock price of €181.10 is trading 10.2% below its estimated GF Value™ of €201.74.
GuruFocus considers Sartorius Stedim Biotech to be Modestly Undervalued.
Key valuation signals for CHIX:DIMP:
Goodwill-to-Asset: 0.37
GF Value™: €201.74 vs. price of €181.10 (10.2% below fair value)
No single metric tells the full story. See the CHIX:DIMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sartorius Stedim Biotech is a leading provider of bioprocessing solutions. It sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs and has a focus on single-use technology. It is a subsidiary of Sartorius AG, which has 71.5% ownership and 83% voting control. The business is geographically diverse, with 35% of sales from the Americas, 42% from Europe, the Middle East, and Africa, 15% from Asia excluding China, and 8% from China.
84GF Score
Get the complete analysis for CHIX:DIMP
Goodwill-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:DIMP has been successfully added to your 
